Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: A randomized dose-response trial

Journal of the American College of Cardiology

Volumn 27, Issue 3, 1996, Pages 575-584

  Leschke, Matthias ^a   Schoebel, Frank Chris ^a   Mecklenbeck, Wolfgang ^a   Stein, Dirk ^a   Jax, Thomas Walter ^a   Müller Gärtner, Hans Wilheim ^a   Strauer, Bodo Eckehard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; UROKINASE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG INTERMITTENT THERAPY; ELECTROCARDIOGRAM; ERYTHROCYTE AGGREGATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOSIS;

EID: 0029972763     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00494-7     Document Type: Article

References (69)

1. Ehrly AM, Schenk JF. Systemisch niedrig dosierte Langzeit-Urokinasetherapie hei schwerster Angina pectoris. Grundlagen und erste Ergebnisse. In: Strauer BE, Ehrly AM, Leschke M, editors, Fortschritte in der kardiovaskulären Rheologie, Munich: Münchner Wissenschaftliche Publikationen, 1987:35-8.
2. Leschke M, Höffken H, Vogt M, Motz W, Strauer BE. Intermittent urokinase therapy as a new strategy concept in untractable angina pectoris. J Am Coll Cardiol 1989;13:16A.
3. Leschke M, Höffken H, Motz W, Blanke H, Schoebel FC, Strauer BE. Chronisch-intermittierende Urokinasetherapie bei therapierefraktärer Angina pectoris. Dtsch Med Wschr 1992;117:81-7.
4. Schoehel FC, Leschke M, Jax TW, Stein D, Strauer BE. Chronic-intermittent urokinase therapy and refractory angina pectoris - a pilot study. Clin Cardiol 1996;19:115-20.
5. Campeau L. Grading of angina pectoris. Circulation 1976;54:522-3.
6. Braunwald E. Unstable angina - a classification. Circulation 1989;80:410-4.
7. Benson H, Mc Callie DP Jr. Angina pectoris and the placebo effect. N Engl J Med 1979;300:1424-9.
8. Parisi AF, Strauss WE, McIntyre KM, Sasahara AA. Consideration in evaluating new antianginal drugs. Circulation 1982;65 Suppl I:I-38-42.
9. Bull U, Kaiser HJ, Dupont F, Uebis R, Kleinhans E, Hanrath P. Methoxyisobutylisnitrile (MIBI) Tc 99m SPECT to establish a correlate to coronary flow reserve, the perfusion reserve, from global and regional myocardial uptake after exercise and rest. Eur J Nucl Med 1990;16:3-9.
10. 201T1 myocardial SPECT: presentation of method. Nucl Med 1986;25:128-33.
11. 201T1 with SPECT. Nucl Med Commun 1988;9:15-23.
12. Mecklenheck W. Nachweis der Wirksamkeit der Urokinasetherapie hei fortgeschrittener KHK mit Hilfe der Myokardszintigraphie. Nuklearmediziner 1992;15:167-72.
13. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-41.
14. Leschke M, Blanke H, Stellwaag M, Motz W, Strauer BE. Hyperfibrinogenämie und pathologische Plasmaviskosität. Dtsch Med Wochenschr 1988; 113:1175-81.
15. Schmid-Schönbein H, Volger E, Klose HJ. Microrheology and light transmission of blood - II. The photometric quantification of red cell aggregate formation and dispersion in flow. Pfluegers Arch 1972;333:140-55.
16. Amsterdam EA, Hughes JL, DeMaria AN, Zelis R, Mason DT. Indirect assessment of myocardial oxygen consumption in the evaluation of mechanisms and therapy of angina pectoris. Am J Cardiol 1974;33:737-4.3.
17. Schmid-Schönbcin H. Interaction of vasomotion and blood rheology in hemodynamics. In: Lowe GDO. Barbend JC, Forbes CD, editors. Clinical Aspects of Blood Viscosity and Cell Deformability. Berlin: Springer-Verlag, 1981:49-65.
18. Chien S. Physiological and pathophysiological significance of hemorheology. In: Chien S, Dormandy J, Ernst E, Mattrai A, editors. Clinical Hemorheology. Dordrecht: Martinus Nijhoff, 1987:125-60.
19. Wolf R, Lichtlen PR. Die Beziehung zwischen Plasmafibrinogen und der Funktion der Kollateralgefäße. Z Kardiol 1995;84:348-59.
20. Gordon RJ, Snyder GK, Tritel H, Taylor WJ. Potential significance of plasma viscosity and hematocrit variations in myocardial ischemia. Am Heart J 1974;87:175-82.
21. Jan K-M, Chien S, Bigger JT. Observations on blood viscosity changes after acute myocardial infarction. Circulation 1975;51:1079-84.
22. Mattrai A, Whittington RB, Skalak R. Biophysics in clinical hemorheolocy. In Ref. 18:9-65.
23. Davies MJ, Bland JM, Hangartner JRW, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary syndromes in sudden ischemic death. Eur Heart J 1989;10:203-8.
24. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326: 310-8.
25. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in vascular occlusion. Circulation 1985;71:699-708.
26. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-27.
27. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
28. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl J Med 1992;326:242-50.
29. Ceriello A, Pirisi M, Giacomello R, et al. Fibrinbogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemostas 1994;71:593-5.
30. Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992;94:93-1117.
31. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1-6.
32. Shelton ME, Forman MB, Virmani R, Bajaj A, Stoney WS, Atkinson JB. A comparison of morphologic and angiographic findings in long-term internal mammary and saphenous vein grafts. J Am Coll Cardiol 1988;11:297-307.
33. Bates ER, Aucron FM, Legrand V, et al. Comparative long-term effects of coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty on regional coronary flow reserve. Circulation 1985;72:833-9.
34. Wilson RF, White CW. Does coronary artery bypass surgery restore normal maximal coronary flow reserve? The effect of diffuse atherosclerosis and focal obstructive lesions. Circulation 1987;76:563-71.
35. Luscher TF, Diederich D, Siebenmann R, et al. Difference between endothelium-dependent relaxation in arterial and venous coronary bypass grafts. N Engl J Med 1988;319:462-7.
36. Wilson RF, Marcus ML, White CW. Effects of coronary bypass surgery and angioplasty on coronary blood flow reserve. Prog Cardiovasc Dis 1988;31: 95-114.
37. Kalan JM, Roberts WC. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necrops analysis of 53 patients, 123 saphenous veins and 1865 five-millimeter segments of veins. Am Heart J 1990;119:1164-84.
38. Cernigliaro C, Sansa M, Campi A, et al. Thrombolytic efficacy of a single intravenous bolus of urokinase in AMI: a dose range clinical trial. Circulation 1994:90 Suppl I:I-168.
39. Wenzel E, Miyashita C, Köhler M, Nienhaus K, Jäger H. Veränderung des Gerinnungs- und Fibrinolysesystems unter Urokinase-Therapie. In: Trühestcin G, editor. Urokinase Therapy. Stuttgart: F.K. Schattauer Verlag, 1981;21-33.
40. Melandri G, Semprini F, Cervi V, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: a double-blind, randomized, placebo-controlled trial. Circulation 1993;88: 2517-23.
41. Quyyumi AA, Diodati JG, Lakatos EE, Bonow RO, Epstein SE. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study. J Am Coll Cardiol 1993;22:635-41.
42. Fujita M, Mikuniya A. Takahashi M, et al. Acceleration of coronary collateral development by heparin in conscious dogs. Jpn Circ J 1987;51: 395-402.
43. Fujita M, Sasayama S, Asanoi H, Nakajima H. Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment. Circulation 1988;77:1022-9.
44. Unger EF, Sheffield CD, Epstein SE. Heparin promotes the formation of cxtracardiac anastomoses in the canine model. Am J Physiol 1991;260: H1625-34.
45. Smith EB, Alexander KM, Massie IB. Insoluble fibrin in human aortic intima. Quantitative studies on the relationship between insoluble fibrinogen and low-density lipoprotein. Atherosclerosis 1976;23:19-25.
46. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990;10:263-75.
47. Bini A, Fenoglia JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibody. Arteriosclerosis 1989;9:109-21.
48. Schneidau A, Harrison MJG, Hurst C, et al. Arterial disease risk factors and angiographic evidence of atheroma of the carotid artery. Stroke 1989;20: 1466-71.
49. Broadhurst P, Kelleher C, Hughes E, et al. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990;85:169-73.
50. Bär FW, Verbeugt FW, Col J, et al. Thrombolysis in patients with unstable angina improves angiographic but not clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation 1992;86:131-7.
51. Schreiber TL, Rizik D, White C, et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992;86:1407-14.
52. The TIMI IIIb Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results from the TIMI IIIb trial. Circulation 1994;89:1545-56.
53. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense tibrinolysis. J Am Coll Cardiol 1987;10:527-9.
54. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1990;55:635-43.
55. Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990;1:481-2.
56. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991;83:937-44.
57. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in-vitro fibrinolytic treatment. Circulation 1992;85:1706-12.
58. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988;77:678-84.
59. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.
60. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989;65:83-94.
61. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992;326:310-8.
62. Romeo F, Rosano GMC, Martuscelli E, et al. Effectiveness of prolonged low dose recombinant tissue-type plasminogen activator for refractory unstable angina. J Am Coll Cardiol 1995;25:1295-9.
63. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis - instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974;33:87-94.
64. Lichtlen PR. Pathophysiology of coronary and myocardial function in angina pectoris: important aspects for drug treatment. Eur Heart J 1985;6 Suppl F:11-25.
65. Maseri A, Chicrchia S, Kaski JC. Mixed angina pectoris. Am J Cardiol 1985;56:30E-3E.
66. Shub C. Stable angina pectoris: 3. Medical treatment. Mayo Clin Proc 1990;65:256-73.
67. Leschke M, Vogt M, Motz W, Strauer BE. Blood rheology as a contributing factor in reduced coronary reserve in systemic hypertension. Am J Cardiol 1990;65:56G-9G.
68. Strauer BE. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 1990;15:775-83.
69. Schoebel FC, Leschke M, Strauer BE. Therapicrefraktäre Angina pectoris - Pathophysiologische Grundlagen und alternative Therapieansätze hei der koronaren Herzkrankheit. Dtsch Med Wochenschr 1995;120: 301-7.